Artelo Biosciences, Inc. (ARTL) vs Jupiter Neurosciences, Inc. (JUNS)
A side-by-side comparison of Artelo Biosciences, Inc. and Jupiter Neurosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARTL
Artelo Biosciences, Inc.
$3.57HealthcareDelayed quote: Oct 6, 2026, 9:58 AM EDT
JUNS
Jupiter Neurosciences, Inc.
$2.48HealthcareDelayed quote: Oct 6, 2026, 9:58 AM EDT
Total return — ARTL vs JUNS
growth of $100 · dividends reinvested · last 2yARTL -94.0% (-75.5%/yr)JUNS -99.4% (-92.3%/yr)ARTL compounded faster over this window
Log scale — wide-divergence pair
ARTL JUNS
ARTL vs JUNS: by the numbers
- •ARTL is the larger company ($1M vs $1M market cap).
- •Both run net losses; ARTL's is the smaller (0.00% vs -14220.12% net margin).
Metrics side by side
Valuation
| Metric | ARTL | JUNS |
|---|---|---|
| P/S ratio | N/A | 18.58 |
| P/B ratio | 0.28 | N/A |
Profitability
| Metric | ARTL | JUNS |
|---|---|---|
| Gross margin | 0.00% | 88.34% |
| Operating margin | 0.00% | -40873.19% |
| Net margin | 0.00% | -14220.12% |
| ROE | -253.57% | N/A |
| ROIC | -219.36% | -709.40% |
Growth (annualized)
| Metric | ARTL | JUNS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -47.77% |
| Total return CAGR (5Y) | -64.27% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.